CNS Pharmaceuticals Inc. CNSP Archives - Page 11 of 23

FridaySep 09, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field

CNS Pharmaceuticals, a Texas-based cancer drug developer, is advancing testing efforts for its lead drug candidates in the fight against glioblastoma (“GBM”) and other tumors Glioblastoma is an aggressive brain cancer that claims the lives of more than 10,000 Americans each year, with more victims worldwide, and it has no known cure CNS Pharmaceuticals’ efforts rely on establishing the safety and effectiveness of its lead candidate, Berubicin Berubicin is an anthracycline (chemotherapy agent) with the apparent ability to cross the blood-brain barrier to attack central nervous system tumors, which grants it a unique status among anthracyclines CNS has shown evidence…

WednesdaySep 07, 2022 1:51 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at H.C. Wainwright 24th Annual Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its CEO John Climaco will present at the H.C. Wainwright 24th Annual Global Investment Conference. The event is being held in New York, New York, and virtually on Sept. 12-14, 2022. A video webcast of the presentation will be accessible for viewing on-demand beginning at 7:00 a.m. ET on Sept. 12 for those registered for the event. The webcast will also be available on the Events page of the company’s website,…

WednesdaySep 07, 2022 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Posts Slight Q2 2022 Performance Improvement; Maintains Priorities and Focus on Advancing its Clinical Development Program for Berubicin

CNS reported a decrease in losses from $3.8 million in Q2 2021 to $3.6 million in Q2 2022, as well as a drop in research and development expenses from $2.7 million to $2.2 million, with an increase in general and administrative expenses from $1.1 million to $1.3 million The company closed the quarter with $9.0 million in cash, and a working capital of approximately $10.3 million which, it is confident, will fund its operations into the 2023 calendar year CNS looks to continue site initiations across the U.S., Italy, France, Spain, and Switzerland, while also pushing for regulatory and ethics…

ThursdaySep 01, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research

When CNS went public in 2019, the funds went primarily into pre-clinical preparation, trial design approval, and drug manufacturing for its potentially pivotal global clinical trial of Berubicin for recurrent glioblastoma multiforme (“GBM”) So far, CNS has received FDA Fast Track Designation on its Berubicin clinical study, inching the company closer to offering a viable solution to the millions of people dealing with GBM, a devastating malignant brain cancer It remains committed to pushing the envelope in terms of research and development of potential GBM treatment, as we ll as brain cancers in general, to offer a viable solution to…

TuesdayAug 30, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product

CNS Pharmaceuticals is currently undertaking a potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine administered after first-line therapy for the treatment of recurrent glioblastoma multiforme (“GBM”) GBM is an aggressive form of cancer that occurs in the brain or spinal cord In the U.S., it affects between 12,000-15,000 new patients annually with a median survival rate of only 14.6 months from its diagnosis CNS’s drug development program is targeting the GBM drug market which is expected to expand at a CAGR of more than 4% between 2020 and 2030 On July 24, 2021, pre-clinical…

TuesdayAug 23, 2022 1:25 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Continues Priority to Advance Clinical Development Program for Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is focused on advancing its clinical program for treating glioblastoma (“GBM”), a brain cancer that has no present cure and few treatment options for patients. The most aggressive primary brain tumor, GBM affects approximately 13,000 new patients each year in the United States with an average survival time of less than one year post diagnosis. “The company’s lead drug candidate is a novel anthracycline named Berubicin that has set itself apart from other potential therapies because of its apparent ability to cross the blood-brain barrier with central nervous system uptake,” reads a recent article. “CNS Pharmaceuticals…

MondayAug 15, 2022 12:25 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2022 Financial Results, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today reported its financial results for the quarter ended June 30, 2022, and provided a clinical update of its anti-cancer drug candidates currently in development. “Within the past six months alone, we have executed on a number of clinical and operational advancements including expanding our global presence with clinical approvals in Spain, France and Switzerland to drive patient enrollment forward, as well as expanding eligibility for patients to participate in our…

FridayAug 12, 2022 12:40 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Positioning Berubicin Clinical Development Program for Success

CNS Pharmaceuticals (NASDAQ: CNSP) is currently recruiting patients for a phase II study evaluating the efficacy and safety of Berubicin, its lead drug candidate for treating glioblastoma multiforme (“GBM”), the most aggressive, deadly and treatment-resistant type of cancer that forms in the brain. Recently, the company announced that the FDA had approved an amendment to the study’s protocol, boosting its Berubicin clinical development program. “The amendment expands eligibility for its potentially pivotal study to patients who have received additional treatments as part of the first-line therapy,” explains a recent article. “The key objectives of the amendment, according to CNS Pharmaceuticals…

ThursdayAug 04, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advances Drug Candidate to Fight Aggressive Brain Cancer Amid Difficult Era for Market

CNS Pharmaceuticals is a U.S.-based drug innovator developing novel chemotherapy agents capable of taking the fight against cancerous tumors across the blood-brain barrier to directly attack cancerous growths of the central nervous system The company’s lead candidate is an anthracycline named Berubicin, which has previously shown promise among glioblastoma (“GBM”) patients in a safety study — particularly for one who remains cancer-free more than 15 years later CNS is enrolling patients in the United States, Italy, France, Spain, and Switzerland, for the global Phase 2 clinical trial to measure Berubicin’s potential to match or exceed the effectiveness of Lomustine, a…

TuesdayAug 02, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM Treatment

CNS Pharmaceuticals is undertaking a Berubicin clinical development program targeting glioblastoma multiforme (“GBM”), the most common and devastating primary malignant brain tumor GBM has an incidence rate of 3.21 per 100,000 in the U.S. and up to 5 per 100,000 globally, with studies noting that the latter figure is rising CNS recently received approval for a protocol amendment as part of its potentially pivotal study evaluating the efficacy and safety of Berubicin for the treatment of GBM The amendment expands eligibility for its potentially pivotal study to patients who have received additional treatments as part of the first-line therapy CNS…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP